A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- new diagnosis of non-small cell lung cancer (NSCLC) OR metastatic (in other areas of the body) or is too advanced for treatment that will cure the cancer - tumor has an epidermal growth factor receptor gene (EGFR) mutation - able to walk and carry out work of a light or sedentary nature, e.g., light house work, office work, but can't do strenuous physical activity - see link to clinicaltrials.gov for complete inclusion & exclusion criteria

Exclusion Criteria:

- history of active interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis - not have fully recovered from surgery, or has surgery planned during the time the participant is expected to be in the study - uncontrolled tumor-related pain

Conditions & Interventions

Interventions:
Drug: Amivantamab, Drug: Chemotherapy: Carboplatin, Drug: Chemotherapy: Pemetrexed, Drug: Lazertinib
Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), non-small cell lung cancer, NSCLC

More Information

Description: This study is being conducted to compare the efficacy of subcutaneous amivantamab plus lazertinib in previously untreated EGFR mutated non-small cell lung cancer OR subcutaneous amivantamab plus chemotherapy after having received prior therapy for EGFR mutated non-small cell lung cancer.
Study Contact: Amanda Garcia - garc0276@umn.edu
Principal Investigator: Manish Patel
Phase: PHASE2
IRB Number: STUDY00023797